Article Text

PDF
I31 Enroll-HD: current status
  1. Olivia Handley1,
  2. Tiago Mestre2,
  3. Jamie Levey3,
  4. Tim McLean1,
  5. Bernhard Landwehrmeyer4,
  6. Cristina Sampaio3 on behalf of the Enroll-HD Steering Committee
  1. 1EHDN, University of Ulm, Germany
  2. 2University of Ottawa, Canada
  3. 3CHDI Management/Foundation, Inc., Princeton, NJ, USA
  4. 4University of Ulm, Germany

Abstract

Background Enroll-HD is a global observational registry study of Huntington’s disease (HD) designed to serve as a platform for clinical research. The first participant was recruited in 2012, and within less than 4 years, the study has in excess of 10 000 participants.

Aims Enroll-HD is a platform designed to facilitate clinical research in Huntington’s disease.

Methods Core data are collected annually on all research participants as part of this multi-centre longitudinal observational study of Huntington’s disease. Data are monitored for quality and accuracy using a risk-based monitoring approach. All sites are required to obtain and maintain local Ethics Committee approvals.

Eligible participants include gene carriers (presymptomatic and manifest) as well as individuals at risk, and controls. Assessments include core data covering motor, cognitive, and behavioural symptoms. Optional assessments include quality of life, physical functioning and work productivity measures. Phenotypic data are available for the research community at regular intervals through a straightforward downloading process, after a rigorous data monitoring process. As part of the annual assessments, Enroll-HD enables the collection of biological samples (lymphocytes, lymphoblastoid cell lines and DNA). Biological samples are also available for distribution from a central repository for clinical research.

Results Currently, Enroll-HD has 10 901 participants recruited from 136 sites in North America, Europe, South America and Australia/New Zealand. Clinical data and biological samples are available to researchers from 4,146 participants (presymptomatic, 21%; manifest HD, 56%, mean CAG repeat expansion: 43.0, range: 36.0; 71.0). Biological samples are available for 98.6% of study participants.

Conclusions Enroll-HD provides high quality clinical data and biological samples. As a research platform, Enroll-HD brings together a novel set of tools for HD clinical research that is easily available for researchers interested in HD and other neurodegenerative diseases.

Acknowledgements Enroll-HD is a longitudinal observational study for Huntington’s disease families intended to accelerate progress towards therapeutics; it is sponsored by CHDI Foundation, a nonprofit biomedical research organisation exclusively dedicated to developing therapeutics for HD. Enroll-HD would not be possible without the vital contribution of the research participants and their families.

  • clinical study
  • global

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.